The research and analysis conducted in Primary Biliary Cholangitis Market report helps clients to predict investment in an emerging market, expansion of market share or success of a new product with the help of global market research analysis. This marketing report has been designed in such a way that it provides very evident understanding of the business environment and Healthcare industry. Nevertheless, this global market research report unravels many business problems very quickly and easily. Due to high demand and the value of market research for the success of different sectors, Primary Biliary Cholangitis Market report is provided that covers many work areas.

Market expectations for likely development openings have been mentioned clearly in the world class Primary Biliary Cholangitis Market research report. Competition analysis has been taken into account while preparing this report. A market analysis has turned into a vital piece of every business to settle on smart choices in the organizations which have been viably carried by experienced analysts. This market report provides best solutions for strategy development and implementation depending on client’s needs to extract tangible results. Businesses can bring about an absolute knowhow of general market conditions and tendencies with the information and data covered in the finest Primary Biliary Cholangitis Market report.

Data Bridge Market Research analyses that the primary biliary cholangitis market was valued at USD 784.81 million in 2021 and is expected to reach USD 1,744.47 million by 2029, registering a CAGR of 10.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Grab Sample Report with Complete Graphs, Charts, and Figures @

Primary biliary cholangitis, also known as primary biliary cirrhosis, is a chronic liver condition in which the bile ducts are gradually damaged. PBC has no known treatment. To control symptoms and reduce the progression of PBC, doctors prescribe medication. Ursodiol aids in the removal of bile from the liver. In many cases, this medication improves liver function and slows the course of liver disease. If ursodeoxycholic acid (UDCA) is ineffective or cannot be tolerated, obeticholic acid is used alone or in combination with it. This treatment lowers bile production while increasing bile flow out of the liver. Other pharmacological choices are available depending on the individual circumstances of each patient and the existence of other medical disorders. If liver function continues to deteriorate after medical treatment, a liver transplant may be required.

Primary Biliary Cholangitis Market Dynamics


·         Increasing prevalence of primary biliary cholangitis

The rising prevalence of primary biliary cholangitis across the globe is estimated to enhance the market's growth. Primary biliary cholangitis (PBC) is an uncommon disease that causes a persistent, progressive liver disorder. It primarily affects women and usually strikes between the ages of 30 and 60.  The tiny bile duct in the liver is usually affected by PBC. Primary biliary cholangitis is split into four phases: stage 1 (no scarring) to stage 4 (cirrhosis). A mix of causes, including autoimmune, genetic, and environmental factors, can cause PBC.

·         Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of primary biliary cholangitis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the primary biliary cholangitis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of primary biliary cholangitis market. Rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market’s growth rate during the forecast period of 2022-2029.

Some of the major players operating in the Primary Biliary Cholangitis market are:

·         F. Hoffmann-La Roche Ltd. (Switzerland)

·         Mylan N.V. (U.S.)

·         Teva Pharmaceutical Industries Ltd. (Ireland)

·         Sanofi (France)

·         Pfizer Inc. (U.S.)

·         GlaxoSmithKline plc (U.K.)

·         Novartis AG (Switzerland)

·         Merck & Co., Inc. (U.S.)

·         Allergan (Ireland)

·         AstraZeneca (U.K.)

·         Johnson & Johnson Private Limited (U.S.)

·         Hikma Pharmaceuticals PLC (U.K.)

·         Bristol-Myers Squibb Company (U.S.)

·         Bayer AG (Germany)

·         Boehringer Ingelheim International GmbH. (Germany)

·         Dr. Reddy’s Laboratories Ltd. (India)

·         Gilead Sciences, Inc. (U.S.)

·         Amgen Inc. (U.S.)

·         Eli Lilly and Company (U.S.)

·         AbbVie Inc. (U.S.)

·         Lupin (India)

·         Allergan (Ireland)

Global Primary Biliary Cholangitis Market Scope

The primary biliary cholangitis market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

·         Liver Transplantation

·         Drug Therapy

·         Ursodeoxycholic acid (UDCA)

·         Obeticholic acid

·         Fibrates

·         Budesonide

·         Others


·         Imaging Tests

·         Magnetic resonance elastography (MRE)

·         Magnetic resonance cholangiopancreatography (MRCP)

·         Ultrasound

·         FibroScan

·         Blood Tests

·         Cholesterol test

·         Antibody tests

·         Liver tests

·         Others

Route of Administration

·         Oral

·         Parenteral

·         Others


·         Hospitals

·         Specialty Clinics

·         Homecare

·         Others

Distribution Channel

·         Hospital Pharmacy

·         Retail Pharmacy

·         Online Pharmacy

·         Others

Browse More about Global Primary Biliary Cholangitis Market Research Report at @

The research examines the characteristics of the target market, as well as recent developments and patterns, industry opportunities, growth rates, sector expansion strategies, and emerging technologies. The Primary Biliary Cholangitis market research report offered a very useful resource that can help stakeholders, manufacturers, decision-makers, and market participants to become familiar with all the factors impacting the growth of the global market. The report includes SWOT, and market analyses to provide a deep and clear understanding of aspects of the Primary Biliary Cholangitis market.

Browse More Reports of Healthcare Domain by DBMR:

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475